(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) slid by a staggering 17.41% in 5 sessions from $8.04 at -17.41, to $6.64 at 10:54 EST on Monday, after five successive sessions in a row of losses. NASDAQ is rising 0.59% to $13,572.33, following the last session’s downward trend.
Novavax’s last close was $6.70, 91.27% below its 52-week high of $76.77.
About Novavax
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-13.07.
Yearly Top and Bottom Value
Novavax’s stock is valued at $6.64 at 10:54 EST, way under its 52-week high of $76.77 and way above its 52-week low of $5.61.
Volume
Today’s last reported volume for Novavax is 1156425 which is 82.35% below its average volume of 5930860.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Novavax’s EBITDA is 0.11.
Moving Average
Novavax’s worth is way below its 50-day moving average of $7.89 and way under its 200-day moving average of $13.03.
More news about Novavax (NVAX).
